

# Andrew L Feldman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4545/andrew-l-feldman-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158 papers	4,725 citations	35 h-index	66 g-index
171 ext. papers	6,268 ext. citations	4.6 avg, IF	5.28 L-index

#	Paper	IF	Citations
158	CA9 expression in breast implant-associated anaplastic large cell lymphoma presenting in a lymph node.. <i>Histopathology</i> , <b>2022</b> ,	7.3	0
157	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 78	7	0
156	RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large cell lymphoma.. <i>Histopathology</i> , <b>2022</b> ,	7.3	0
155	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients 65 Years Receiving Bendamustine-Rituximab. <i>Blood</i> , <b>2021</b> , 138, 3517-3517	2.2	0
154	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. <i>Blood</i> , <b>2021</b> , 138, 2429-2429	2.2	1
153	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. <i>Blood</i> , <b>2021</b> , 138, 1326-1326	2.2	0
152	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , <b>2021</b> , 45, 550-557	6.7	3
151	Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 620435	5.3	0
150	How I Diagnose Anaplastic Large Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , <b>2021</b> , 155, 479-497	4.7	2
149	Chromosomal Junction Detection from Whole-Genome Sequencing on Formalin-Fixed, Paraffin-Embedded Tumors. <i>Journal of Molecular Diagnostics</i> , <b>2021</b> , 23, 375-388	5.1	0
148	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. <i>Haematologica</i> , <b>2021</b> , 106, 2682-2693	6.6	12
147	Body mass index and survival of patients with lymphoma. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2671-2678	1.9	0
146	Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 130	7	5
145	Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. <i>Modern Pathology</i> , <b>2021</b> , 34, 2154-2167	9.8	6
144	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , <b>2021</b> , 35, 522-533	10.7	9
143	Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma. <i>Haematologica</i> , <b>2021</b> , 106, 1714-1724	6.6	10
142	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. <i>Blood</i> , <b>2021</b> , 137, 513-523	2.2	1

141 The Spectrum of Anaplastic Large-cell Lymphoma **2021**, 129-144

140 Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. *Clinical Cancer Research*, **2021**, 27, 6039-6053 12.9 3

139 Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. *Modern Pathology*, **2021**, 9.8 1

138 Coactivation of NF- $\kappa$ B and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. *Blood*, **2020**, 135, 108-120 2.2 8

137 Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. *Blood Advances*, **2020**, 4, 1917-1926 7.8 24

136 Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma. *Academic Pathology*, **2020**, 7, 2374289530901813

135 Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma. *Journal of Clinical Oncology*, **2020**, 38, 1102-1111 2.2 27

134 Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. *Blood*, **2020**, 136, 35-36 2.2 0

133 High-Dimensional and Single-Cell Transcriptome Analysis of AITL Tumor Microenvironment Reveals Gross Expansion of Novel Dysfunctional CD8+ T Cell Populations, Global Shift in B Cell Phenotypes. *Blood*, **2020**, 136, 42-43 2.2

132 Body Mass Index and Survival of Patients with Lymphoma. *Blood*, **2020**, 136, 2-3 2.2

131 Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage Repair. *Blood*, **2020**, 136, 17-18 2.2

130 Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. *Blood*, **2020**, 136, 36-37.2

129 High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. *Blood*, **2020**, 136, 17-18 2.2

128 Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 rearrangements in Anaplastic Large Cell Lymphoma. *Blood*, **2020**, 136, 22-23 2.2

127 Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. *Blood*, **2020**, 136, 26-27 2.2 0

126 Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. *Blood*, **2020**, 136, 7-8 2.2

125 Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases*, **2020**, 71, 1221-1228 11.6 12

124 Targeting epigenetic regulators in the treatment of T-cell lymphoma. *Expert Review of Hematology*, **2020**, 13, 127-139 2.8 7

123	Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract. <i>Leukemia</i> , <b>2020</b> , 34, 1467-1471	10.7	2
122	PD-L1 expression in anaplastic large cell lymphoma. <i>Modern Pathology</i> , <b>2020</b> , 33, 1232-1233	9.8	1
121	American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. <i>Annals of Diagnostic Pathology</i> , <b>2020</b> , 49, 151623	2.2	2
120	Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma. <i>Journal of Hematopathology</i> , <b>2020</b> , 13, 231-238	0.4	3
119	Reply to M. Romero et al. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2819-2820	2.2	1
118	Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing. <i>Histopathology</i> , <b>2020</b> , 76, 481-485	7.3	3
117	"Double-hit" of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative. <i>Blood</i> , <b>2020</b> , 135, 700	2.2	6
116	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 73	7	19
115	Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. <i>Blood</i> , <b>2019</b> , 134, 2159-2170	2.2	45
114	Recurrent mutations in ALK-negative anaplastic large cell lymphoma. <i>Blood</i> , <b>2019</b> , 133, 2776-2789	2.2	23
113	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. <i>Haematologica</i> , <b>2019</b> , 104, e562-e565	6.6	14
112	Host genetic variation in tumor necrosis factor and nuclear factor- $\kappa$ B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E153-E155	7.1	1
111	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 658-666	7.1	9
110	Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. <i>British Journal of Haematology</i> , <b>2019</b> , 186, e24-e27	4.5	6
109	Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , <b>2019</b> , 186, e28-e31	4.5	25
108	Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features. <i>Journal of Cutaneous Pathology</i> , <b>2019</b> , 46, 637-644	1.7	9
107	Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. <i>Expert Review of Hematology</i> , <b>2019</b> , 12, 833-843	2.8	9
106	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , <b>2019</b> , 134, 1289-1297	2.2	19

105	SIRPα expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 84	7	16
104	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 467-467	2.2	16
103	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , <b>2019</b> , 134, 69-69	2.2	3
102	Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 1517-1517	2.2	
101	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , <b>2019</b> , 134, 1480-1480	2.2	
100	Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 1604-1604	2.2	1
99	Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). <i>Aesthetic Surgery Journal</i> , <b>2019</b> , 39, S14-S20	2.4	15
98	Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. <i>Clinical Epidemiology</i> , <b>2019</b> , 11, 987-996	5.9	3
97	Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E62-E64	7.1	9
96	Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas. <i>Small GTPases</i> , <b>2019</b> , 10, 33-39	2.7	10
95	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. <i>Lancet Oncology</i> , <b>2018</b> , 19, 549-561	21.7	112
94	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , <b>2018</b> , 132, 49-58	2.2	90
93	In situ neoplasia in lymph node pathology. <i>Seminars in Diagnostic Pathology</i> , <b>2018</b> , 35, 76-83	4.3	6
92	STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. <i>Human Pathology</i> , <b>2018</b> , 73, 74-81	3.7	23
91	SVAtools for junction detection of genome-wide chromosomal rearrangements by mate-pair sequencing (MPseq). <i>Cancer Genetics</i> , <b>2018</b> , 221, 1-18	2.3	57
90	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , <b>2018</b> , 24, 679-690	50.5	659
89	Recurrent fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. <i>Blood</i> , <b>2018</b> , 131, 2262-2266	2.2	45
88	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 73	7	19

87	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , <b>2018</b> , 78, 4086-4096	10.1	18
86	Copy number variant analysis using genome-wide mate-pair sequencing. <i>Genes Chromosomes and Cancer</i> , <b>2018</b> , 57, 459-470	5	38
85	Inferior survival in high-grade B-cell lymphoma with and and/or rearrangements is not associated with gene rearrangements. <i>Haematologica</i> , <b>2018</b> , 103, 1899-1907	6.6	31
84	Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. <i>Blood</i> , <b>2018</b> , 132, 544-547.	2.2	60
83	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. <i>Blood</i> , <b>2018</b> , 132, 1702-1702	2.2	3
82	Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. <i>Blood</i> , <b>2018</b> , 132, 2878-2878	2.2	
81	Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 3579-3579	2.2	
80	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. <i>Blood</i> , <b>2018</b> , 132, 4140-4140	2.2	
79	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <i>Haematologica</i> , <b>2018</b> , 103, 297-303	6.6	14
78	Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 110	7	15
77	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with rearrangements. <i>Blood</i> , <b>2018</b> , 132, 1386-1398	2.2	44
76	Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 97	7	16
75	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , <b>2018</b> , 9, 4182	17.4	8
74	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1543-1550	7.1	8
73	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 644-653	4.5	15
72	Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 239-249	2.8	60
71	Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. <i>Human Pathology</i> , <b>2017</b> , 64, 19-27	3.7	31
70	Lymphoma classification update: B-cell non-Hodgkin lymphomas. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 405-415	2.8	32

69	and rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. <i>Blood</i> , <b>2017</b> , 130, 554-557	2.2	68
68	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 752-758	7.1	11
67	Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2342-2348	1.9	5
66	Genetic Landscape and Classification of Peripheral T Cell Lymphomas. <i>Current Oncology Reports</i> , <b>2017</b> , 19, 28	6.3	32
65	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4019-4026	2.2	35
64	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , <b>2017</b> , 46, 1753-1754	7.8	35
63	Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia. <i>Blood</i> , <b>2017</b> , 130, 1387	2.2	1
62	Nodular Lymphocyte Predominant Hodgkin Lymphoma of the Ileum. <i>Case Reports in Pathology</i> , <b>2017</b> , 2017, 5981013	0.9	0
61	The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis. <i>Blood</i> , <b>2017</b> , 130, 822-822	2.2	6
60	Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. <i>Oncotarget</i> , <b>2017</b> , 8, 26245-26255	3.3	13
59	The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival. <i>Blood</i> , <b>2017</b> , 130, 914-914	2.2	1
58	Genetics of anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 21-7	1.9	31
57	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1234-45	2.2	77
56	Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management. <i>Expert Review of Hematology</i> , <b>2016</b> , 9, 137-50	2.8	15
55	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , <b>2016</b> , 128, 155-155	2.2	1
54	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". <i>Blood</i> , <b>2016</b> , 128, 1750-1750	2.2	2
53	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , <b>2016</b> , 128, 3034-3034	2.2	4
52	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , <b>2016</b> , 128, 4392-4392	2.2	7

51	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , <b>2016</b> , 128, 5299-5299	2.2	1
50	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 920-920	2.2	
49	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. <i>Blood</i> , <b>2016</b> , 128, 107-107	2.2	
48	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 2935-2935	2.2	
47	Novel Mutations in NOTCH and Altered Wnt/ $\beta$ Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 4103-4103	2.2	1
46	Retinoic Acid Receptor Alpha Expression Drives Cell-Cycle Progression and Is Associated with Increased Sensitivity to Retinoids in Peripheral T-Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1749-1749	2.2	
45	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. <i>American Journal of Surgical Pathology</i> , <b>2016</b> , 40, 36-43	6.7	70
44	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 179-84	7.1	30
43	Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al. <i>Haematologica</i> , <b>2016</b> , 101, e269-70	6.6	13
42	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 1096-1101	7.1	137
41	Cyclin D1 expression in peripheral T-cell lymphomas. <i>Modern Pathology</i> , <b>2016</b> , 29, 1306-1312	9.8	12
40	Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma. <i>Modern Pathology</i> , <b>2015</b> , 28, 359-66	9.8	10
39	Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. <i>Advances in Anatomic Pathology</i> , <b>2015</b> , 22, 29-49	5.1	75
38	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- $\kappa$ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , <b>2015</b> , 125, 3118-27	2.2	47
37	Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2015</b> , 23, 580-9	9.9	8
36	Secondary cutaneous involvement by systemic anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma with 6p25.3 rearrangement. <i>Histopathology</i> , <b>2015</b> , 67, 932-5	7.3	3
35	Mutations Targeting the ErbB Pathway and MSC in Peripheral T-Cell Lymphoma. <i>Blood</i> , <b>2015</b> , 126, 2681-2681	2.2	3
34	Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , <b>2014</b> , 2014, 130-44	4.8	199

33	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , <b>2014</b> , 124, 1473-80	2.2	294
32	RVboost: RNA-seq variants prioritization using a boosting method. <i>Bioinformatics</i> , <b>2014</b> , 30, 3414-6	7.2	21
31	Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2862-72	12.9	68
30	Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , <b>2014</b> , 2014, 66-75	4.8	40
29	Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. <i>Genes Chromosomes and Cancer</i> , <b>2013</b> , 52, 1097-102	5	45
28	Clonal Relationships Between Malignant Lymphomas and Histiocytic/Dendritic Cell Tumors. <i>Surgical Pathology Clinics</i> , <b>2013</b> , 6, 619-29	3.9	5
27	Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1173-81	6.7	125
26	ITK/SYK translocation in angioimmunoblastic T-cell lymphoma. <i>American Journal of Surgical Pathology</i> , <b>2013</b> , 37, 1456-7	6.7	43
25	t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. <i>PLoS ONE</i> , <b>2013</b> , 8, e53767	3.7	29
24	In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy. <i>Blood</i> , <b>2013</b> , 122, 844-844	2.2	3
23	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , <b>2013</b> , 122, 76-76	2.2	1
22	Deep Proteomic Profiling Predicts Differential Chemosensitivity In Anaplastic Large Cell Lymphoma Cell Lines. <i>Blood</i> , <b>2013</b> , 122, 1670-1670	2.2	
21	Comparison Of Single Nucleotide Mutations (SNVs) and Copy Number Variants (CNVs) Detection In Formalin Fixed Paraffin Embedded (FFPE) and Paired Frozen Tumor Tissues Using Target Capture and Sequencing Approach. <i>Blood</i> , <b>2013</b> , 122, 1784-1784	2.2	
20	GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS. <i>Blood</i> , <b>2013</b> , 122, 841-841	2.2	
19	Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders. <i>Modern Pathology</i> , <b>2012</b> , 25, 983-92	9.8	42
18	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. <i>Blood</i> , <b>2012</b> , 120, 2280-9	2.2	164
17	T(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 Via STAT5. <i>Blood</i> , <b>2012</b> , 120, 1567-1567	2.2	
16	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. <i>Blood</i> , <b>2012</b> , 120, 2702-2702	2.2	

15	Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. <i>Blood</i> , <b>2011</b> , 117, 915-9	2.2	223
14	Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. <i>Journal of Pathology</i> , <b>2011</b> , 223, 496-510	9.4	107
13	Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A. <i>Pediatric Blood and Cancer</i> , <b>2011</b> , 56, 307-10	3	45
12	Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. <i>Modern Pathology</i> , <b>2011</b> , 24, 596-605	9.8	127
11	ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone-Modifying Gene Expression Signature. <i>Blood</i> , <b>2011</b> , 118, 88-88	2.2	1
10	UCH-L1 Is a Novel Regulator of mTOR Signaling That May Predict a Poor Response to mTOR Inhibition in Patients with B-Cell Lymphoma,. <i>Blood</i> , <b>2011</b> , 118, 3691-3691	2.2	
9	PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. <i>Modern Pathology</i> , <b>2010</b> , 23, 593-602	9.8	58
8	Massively Parallel Mate Pair DNA Library Sequencing for Translocation Discovery: Recurrent t(6;7)(p25.3;q32.3) Translocations In ALK-Negative Anaplastic Large Cell Lymphomas. <i>Blood</i> , <b>2010</b> , 116, 633-633	2.2	1
7	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. <i>Blood</i> , <b>2010</b> , 116, 140-140	2.2	
6	A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. <i>Blood</i> , <b>2009</b> , 113, 5206-16	2.2	40
5	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. <i>Blood</i> , <b>2009</b> , 114, 2149-58	2.2	162
4	Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. <i>Modern Pathology</i> , <b>2008</b> , 21, 455-63	9.8	169
3	Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization. <i>American Journal of Clinical Pathology</i> , <b>2008</b> , 130, 178-85	1.9	39
2	Diagnostic uses of Pax5 immunohistochemistry. <i>Advances in Anatomic Pathology</i> , <b>2007</b> , 14, 323-34	5.1	53
1	Syk Tyrosine Kinase Is Overexpressed in the Majority of Peripheral T- and NK-Cell Lymphomas, and Represents a Potential Therapeutic Target.. <i>Blood</i> , <b>2007</b> , 110, 690-690	2.2	3